Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 138.50 GBp
Change Today 0.00 / 0.00%
Volume 13.2K
As of 11:30 AM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

summit therapeutics plc (SUMM) Snapshot

Open
138.50 GBp
Previous Close
138.50 GBp
Day High
138.50 GBp
Day Low
138.50 GBp
52 Week High
03/2/15 - 185.00 GBp
52 Week Low
07/22/14 - 101.25 GBp
Market Cap
84.5M
Average Volume 10 Days
37.6K
EPS TTM
-0.29 GBp
Shares Outstanding
61.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUMMIT THERAPEUTICS PLC (SUMM)

Related News

No related news articles were found.

summit therapeutics plc (SUMM) Related Businessweek News

No Related Businessweek News Found

summit therapeutics plc (SUMM) Details

Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focusses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a fatal muscle wasting disease; and infections caused by Clostridium difficile bacteria (CDI). The company develops SMT C1100, an utrophin modulator that is in Phase Ib trial for the treatment of DMD; and SMT 19969, a novel antibiotic, which is in Phase II placebo controlled proof of concept clinical trial for the treatment of CDI. It has a technology license agreement with Bristol-Myers Squibb to access the Seglin technology for the identification and development of drug candidates. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc is headquartered in Abingdon, the United Kingdom.

25 Employees
Last Reported Date: 05/7/15

summit therapeutics plc (SUMM) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 330.0K GBP
Chief Financial Officer
Total Annual Compensation: 198.5K GBP
Compensation as of Fiscal Year 2015.

summit therapeutics plc (SUMM) Key Developments

Summit Corporation plc Announces Audited Consolidated Earnings Results for the Fiscal Year Ended January 31, 2015

Summit Corporation plc announced audited consolidated earnings results for the fiscal year ended January 31, 2015. For the year, the company’s operating loss was £12,711,000 against £6,709,000 a year ago. Loss before income tax was £12,660,000 against £6,700,000 a year ago. Loss for the year attributable to owners of the parent was £11,363,000 or 0.29 pence basic and diluted per share against £6,093,000 or 0.30 pence basic and diluted per share a year ago. This was driven by an increase in research and development investment, as well as an overall increase in general and administration costs. Net cash used in operating activities was £11,325,000 against £5,869,000 a year ago. This was driven by an increase in research and development investment, as well as an overall increase in general and administration costs. Purchase of property, plant and equipment was £35,000 against £37,000 a year ago. Purchase of intangible assets was £0.00 against £10,000 a year ago.

Summit Therapeutics plc Announces Board Changes

Summit Therapeutics plc announced a number of changes to the Board of Directors.  Mr. Leopoldo Zambeletti was appointed as a Non Executive Director in May 2014.  He is a highly respected and experienced investment banker and brings expertise in a range of areas, including mergers and acquisitions, equity financings, and product outlicensing.  Ms. Valerie Andrews joined the Board in September 2014 as a NonExecutive Director.  She brings a broad set of commercial and legal skills from a career in the healthcare and life sciences industry that included most recently serving as General Counsel for the NASDAQ listed company Vertex Pharmaceuticals Inc.  In February 2015, Mr. David Wurzer was appointed to the Board as a NonExecutive Director and brings extensive experience in financial and business matters related to the pharmaceutical and biotechnology industries having held a number of senior executive and board level positions.  Ms. Andrews and Mr. Wurzer are both based in the US.  Mr. Jim Mellon stepped down as a NonExecutive Director in December 2014 due to the pressure of his other work responsibilities.

Summit Therapeutics plc to Report Fiscal Year 2015 Results on May 06, 2015

Summit Therapeutics plc announced that they will report fiscal year 2015 results on May 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SUMM:LN 138.50 GBp 0.00

SUMM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SUMM.
View Industry Companies
 

Industry Analysis

SUMM

Industry Average

Valuation SUMM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUMMIT THERAPEUTICS PLC, please visit www.summitplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.